Insurance Denied Dermatology Treatment? How to Appeal

Dermatological conditions range from minor nuisances to life-threatening diseases. Psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and skin cancer all require medical treatment — yet insurance companies frequently deny dermatology claims by misclassifying medically necessary treatment as cosmetic, applying overly restrictive step therapy, or disputing the medical necessity of biologic therapies. The American Academy of Dermatology (AAD) publishes evidence-based guidelines for virtually every major skin condition, and these guidelines are your primary tool in challenging a wrongful denial.

Why Insurers Deny Dermatology Claims

• "Cosmetic" misclassification: Labeling medically necessary treatment as cosmetic — one of the most damaging and often wrongful denial types in dermatology. Acne causing permanent scarring, psoriasis affecting quality of life, and many other dermatological conditions have a clear medical basis even when appearance is also affected
• Biologic therapy step therapy: For moderate-to-severe psoriasis, atopic dermatitis, and hidradenitis suppurativa, biologics are first-line or early-line treatments in AAD guidelines — yet insurers routinely require patients to fail multiple topical therapies, phototherapy, and conventional systemic agents before approving biologics
• Not medically necessary for prescription topicals: Insurers deny higher-potency topical steroids, calcineurin inhibitors (tacrolimus, pimecrolimus), or newer agents (tapinarof, roflumilast) using internal criteria that don't reflect current guidelines
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization lapsed: Biologic injections, phototherapy sessions, and many dermatology procedures require prior authorization; lapsed auth causes denial regardless of medical appropriateness
• Phototherapy frequency limits: Narrow-band UVB and excimer laser therapy have strong clinical evidence for psoriasis, vitiligo, and atopic dermatitis, but plans may limit sessions below what guidelines recommend

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered charge — cosmetic), CO-197 (prior authorization required), B15 (authorization not obtained).

How to Appeal a Dermatology Denial

Step 1: Identify the Denial Basis

Cosmetic misclassification requires a different rebuttal than a step therapy dispute, which differs from a prior authorization lapse. Determine which category your denial falls into before building your appeal.

Step 2: Establish Medical Necessity with Validated Severity Scores

Document disease severity with validated, objective tools that dermatologists and External Independent Review: Complete Guide" class="auto-link">external reviewers recognize. For psoriasis: Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) — biologic eligibility is typically supported when PASI >10 or DLQI >10, or when special body areas are involved (hands, feet, face, genitalia, nails). For atopic dermatitis: IGA (Investigator Global Assessment) or EASI (Eczema Area and Severity Index) score. For hidradenitis suppurativa: Hurley stage and IHS4 score. Photographic documentation of skin involvement is appropriate and should be included with patient consent.

Step 3: Cite AAD Clinical Guidelines for the Specific Condition

The AAD and National Psoriasis Foundation (NPF) joint guidelines recommend biologic therapy for patients with moderate-to-severe plaque psoriasis — adalimumab (Humira), secukinumab (Cosentyx), ixekizumab (Taltz), guselkumab (Tremfya), risankizumab (Skyrizi), bimekizumab (Bimzelx). For atopic dermatitis, AAD guidelines support dupilumab (Dupixent) for moderate-to-severe disease not adequately controlled with topicals; tralokinumab (Adbry) and lebrikizumab (Ebglyss) are additional FDA-approved biologics. For hidradenitis suppurativa (L73.2), adalimumab has been FDA-approved since 2015 and secukinumab received HS approval in 2023; USHS Foundation guidelines support early biologic use for patients not responding to antibiotics.

Step 4: Challenge Cosmetic Misclassification

When a dermatology claim is denied as cosmetic, the key arguments are: (1) The condition causes measurable functional impairment — psoriasis causes pain, joint involvement (psoriatic arthritis affects up to 30% of patients), and psychological distress documented with DLQI score; (2) The treatment addresses a diagnosed disease, not appearance — cite ICD-10 codes L40.0 (plaque psoriasis), L20.89 (atopic dermatitis), L73.2 (hidradenitis suppurativa) to establish the medical nature of the condition; (3) For acne with risk of permanent scarring, isotretinoin is medically necessary — denial as cosmetic for severe nodulocystic acne (ICD-10 L70.0, L70.3) applies an incorrect and unsupportable standard.

Step 5: Have Your Dermatologist Write a Detailed Medical Necessity Letter

The letter should specify: diagnosis with ICD-10 code; validated severity score; all prior therapies tried with documented outcomes and reasons for inadequacy; why the denied treatment is medically necessary; and the specific AAD guideline supporting the treatment. Request peer-to-peer review — dermatologists are highly effective advocates in these calls for biologic authorizations.

Step 6: Request External Review for Biologic and Cosmetic Disputes

Dermatology denials involving biologics or cosmetic misclassification are well-supported at external review when AAD guideline evidence and validated severity scores are presented. Request a reviewer with dermatology expertise.

What to Include in Your Appeal

• ICD-10 diagnosis code and physician diagnosis documentation: Establishing the medical basis for treatment
• Validated severity score: DLQI, PASI, IGA, or condition-specific equivalent with documented score
• Prior treatment history: All topical agents, systemic medications, and phototherapy tried with outcomes and reasons for inadequacy
• Dermatologist letter of medical necessity: Citing the specific AAD guideline section supporting the denied treatment
• FDA approval letter for the biologic: If applicable, confirming the medication is approved for your specific condition

Fight Back With ClaimBack

Dermatology denials — especially cosmetic misclassifications and biologic step therapy disputes — are among the most reversible insurance rejections when the right clinical evidence is assembled. ClaimBack helps you build a comprehensive appeal with the AAD guideline citations, severity documentation, and legal arguments that overturn these denials. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal